Prognostic Value of Serum Interleukin-6 (IL-6) and Soluble Interleukin-6 Receptor (sIL-6R) in Severe Coronavirus Disease (COVID-19) Pneumonia Treated With Tocilizumab - a Prospective Single Center Study (UHID-COVID19)
Latest Information Update: 07 Jun 2022
At a glance
- Drugs Tocilizumab (Primary) ; Hydroxychloroquine; Lopinavir/ritonavir; Remdesivir
- Indications COVID-19 pneumonia; Hypoxaemia; SARS-CoV-2 acute respiratory disease
- Focus Biomarker; Therapeutic Use
- Acronyms UHID-COVID19
- 10 Nov 2020 Status changed from not yet recruiting to recruiting.
- 05 Jun 2020 Planned End Date changed from 15 Apr 2021 to 15 May 2021.
- 05 Jun 2020 Planned initiation date changed from 16 Apr 2020 to 16 Jun 2020.